Atacicept R&D Cost Gone, ZymoGenetics Makes Plans
This article was originally published in The Pink Sheet Daily
Executive Summary
Recothrom launch gains momentum as P&T committees meet, GPO deals are forged.
You may also be interested in...
Refocusing ZymoGenetics Cuts Staff, Seeds Pipeline Of Private Startup Firm
In a deal that resembles a spin-out but is termed an arms-length transaction, ZymoGenetics transfers eight preclinical programs to Seattle Life Sciences for future considerations, including an equity stake.
Refocusing ZymoGenetics Cuts Staff, Seeds Pipeline Of Private Startup Firm
In a deal that resembles a spin-out but is termed an arms-length transaction, ZymoGenetics transfers eight preclinical programs to Seattle Life Sciences for future considerations, including an equity stake.
Co-Development Deal Brings Bristol A Novel Interferon, ZymoGenetics Much-Needed Cash
Formerly legal adversaries, the two companies will co-develop PEG-interferon lambda, currently in Phase Ib for hepatitis C.